{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:37:52Z","timestamp":1794663472743,"version":"4.9.1"},"reference-count":34,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with anti-tumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed\/ refractory mature B-cell tumors. Dose escalation followed a 3+3 design; patients received oral sovleplenib (200-800 mg once daily [q.d.] or 200 mg twice daily [b.i.d.], 28-day cycles). During dose expansion, patients were enrolled into four cohorts per lymphoma classification and treated at the recommended phase II dose (RP2D) (clinicaltrials gov. Identifier: NCT02857998). Overall, 134 Chinese patients were enrolled (dose escalation, N=27; dose expansion, N=107). Five patients experienced dose-limiting toxicities: one each of amylase increased (200 mg q.d.), febrile neutropenia (800 mg q.d.), renal failure (800 mg q.d.), hyperuricemia and blood creatine phosphokinase increased (200 mg b.i.d.) and blood bilirubin increased and pneumonia (200 mg b.i.d.). RP2D was determined as 600 mg (&gt;65 kg) or 400 mg (\u226465 kg) q.d.. The primary efficacy end point of independent review committee-assessed objective response rate in indolent B-cell lymphoma was 50.8% (95% confidence interval: 37.5- 64.1) in 59 evaluable patients at RP2D (follicular lymphoma: 60.5%, marginal zone lymphoma: 28.6%, lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia, 0%). The most common (\u226510% patients) grade \u22653 treatment-related adverse events in the dose-expansion phase were decreased neutrophil count (29.9%), pneumonia (12.1%) and decreased white blood cell count (11.2%). Pharmacokinetic exposures increased dose-proportionally with ascending dose levels from 200-800 mg, without observed saturation. Sovleplenib showed anti-tumor activity in relapsed\/refractory B-cell lymphoma with acceptable safety. Further studies are warranted.<\/jats:p>","DOI":"10.3324\/haematol.2022.282401","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:48:54Z","timestamp":1705549734000},"page":"2165-2176","source":"Crossref","is-referenced-by-count":3,"title":["Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors"],"prefix":"10.3324","volume":"109","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxiu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"63297","unstructured":"International Agency for Research on Cancer. Cancer fact sheets. 2022."},{"key":"63298","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-249.","DOI":"10.3322\/caac.21660"},{"key":"63299","doi-asserted-by":"crossref","unstructured":"Sun J, Yang Q, Lu Z. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012; 138(3):429-434.","DOI":"10.1309\/AJCP7YLTQPUSDQ5C"},{"key":"63300","doi-asserted-by":"crossref","unstructured":"Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol. 2017; 28(9):2094-2106.","DOI":"10.1093\/annonc\/mdx189"},{"key":"63301","doi-asserted-by":"crossref","unstructured":"Stegemann M, Denker S, Schmitt CA. DLBCL 1L-what to expect beyond R-CHOP?. Cancers (Basel). 2022; 14(6):1453.","DOI":"10.3390\/cancers14061453"},{"key":"63302","doi-asserted-by":"crossref","unstructured":"Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene. 2001; 20(30):3969-3978.","DOI":"10.1038\/sj.onc.1204515"},{"key":"63303","doi-asserted-by":"crossref","unstructured":"Chen L, Monti S, Juszczynski P. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008; 111(4):2230-2237.","DOI":"10.1182\/blood-2007-07-100115"},{"key":"63304","doi-asserted-by":"crossref","unstructured":"Efremov DG, Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs. 2011; 20(5):623-636.","DOI":"10.1517\/13543784.2011.570329"},{"key":"63305","doi-asserted-by":"crossref","unstructured":"Awan FT, Thirman MJ, Patel-Donnelly D. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. 2019; 60(8):1972-1977.","DOI":"10.1080\/10428194.2018.1562180"},{"key":"63306","doi-asserted-by":"crossref","unstructured":"Cheng S, Coffey G, Zhang XH. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood. 2011; 118(24):6342-6352.","DOI":"10.1182\/blood-2011-02-333773"},{"key":"63307","doi-asserted-by":"crossref","unstructured":"Leseux L, Hamdi SM, Al Saati T. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006; 108(13):4156-4162.","DOI":"10.1182\/blood-2006-05-026203"},{"key":"63308","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Sharman J, Sweetenham J. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010; 115(13):2578-2585.","DOI":"10.1182\/blood-2009-08-236471"},{"key":"63309","doi-asserted-by":"crossref","unstructured":"Currie KS, Kropf JE, Lee T. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014; 57(9):3856-3873.","DOI":"10.1021\/jm500228a"},{"key":"63310","doi-asserted-by":"crossref","unstructured":"Bussel J, Arnold DM, Grossbard E. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93(7):921-930.","DOI":"10.1002\/ajh.25125"},{"key":"63311","doi-asserted-by":"crossref","unstructured":"Bussel JB, Arnold DM, Boxer MA. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019; 94(5):546-553.","DOI":"10.1002\/ajh.25444"},{"key":"63312","doi-asserted-by":"crossref","unstructured":"Flinn IW, Bartlett NL, Blum KA. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016; 54:11-17.","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"63313","doi-asserted-by":"crossref","unstructured":"Sharman J, Hawkins M, Kolibaba K. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015; 125(15):2336-2343.","DOI":"10.1182\/blood-2014-08-595934"},{"key":"63314","doi-asserted-by":"crossref","unstructured":"Andorsky DJ, Kolibaba KS, Assouline S. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019; 184(2):215-222.","DOI":"10.1111\/bjh.15552"},{"key":"63315","doi-asserted-by":"crossref","unstructured":"Hamlin PA, Flinn IW, Wagner-Johnston N. Efficacy and safety of the dual SYK\/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: results of a phase I study. Am J Hematol. 2019; 94(4):e90-e93.","DOI":"10.1002\/ajh.25387"},{"key":"63316","doi-asserted-by":"crossref","unstructured":"Coffey G, Betz A, DeGuzman F. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014; 351(3):538-548.","DOI":"10.1124\/jpet.114.218164"},{"key":"63317","doi-asserted-by":"crossref","unstructured":"Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol. 2017; 10(1):145.","DOI":"10.1186\/s13045-017-0512-1"},{"key":"63318","doi-asserted-by":"crossref","unstructured":"Lam B, Arikawa Y, Cramlett J. Discovery of TAK-659 an orally available investigational inhibitor of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett. 2016; 26(24):5947-5950.","DOI":"10.1016\/j.bmcl.2016.10.087"},{"key":"63319","doi-asserted-by":"crossref","unstructured":"Cai Y, He J, Wu Z. Preclinical pharmacology characterization of sovleplenib (HMPL-523), an orally available Syk inhibitor. J Pharmacol Exp Ther. 2024; 388(1):156-170.","DOI":"10.1124\/jpet.123.001752"},{"key":"63320","doi-asserted-by":"crossref","unstructured":"Yang N, Deng W, Sun Q. HMPL-523, a novel SYK inhibitor showed anti-tumor activities in vitro and in vivo. Blood. 2016; 128(22):3970-3970.","DOI":"10.1182\/blood.V128.22.3970.3970"},{"key":"63321","doi-asserted-by":"crossref","unstructured":"Gordon LI, Kaplan JB, Popat R. Phase I study of TAK-659, an investigational, dual SYK\/FLT3 inhibitor, in patients with B-cell lymphoma. Clin Cancer Res. 2020; 26(14):3546-3556.","DOI":"10.1158\/1078-0432.CCR-19-3239"},{"key":"63322","doi-asserted-by":"crossref","unstructured":"Burke JM, Shustov A, Essell J. An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(8):e327-e331.","DOI":"10.1016\/j.clml.2018.05.022"},{"key":"63323","doi-asserted-by":"crossref","unstructured":"Efremov DG, Turkalj S, Laurenti L. Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies. Cancers (Basel). 2020; 12(6):1396.","DOI":"10.3390\/cancers12061396"},{"key":"63324","doi-asserted-by":"crossref","unstructured":"Sharman J, Di Paolo J. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. Ther Adv Hematol. 2016; 7(3):157-170.","DOI":"10.1177\/2040620716636542"},{"key":"63325","doi-asserted-by":"crossref","unstructured":"Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016; 29(10):1118-1142.","DOI":"10.1038\/modpathol.2016.92"},{"key":"63326","doi-asserted-by":"crossref","unstructured":"Ghia P, Strola G, Granziero L. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002; 32(5):1403-1413.","DOI":"10.1002\/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO;2-Y"},{"key":"63327","doi-asserted-by":"crossref","unstructured":"Reinart N, Nguyen PH, Boucas J. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood. 2013; 121(5):812-821.","DOI":"10.1182\/blood-2012-05-431452"},{"key":"63328","doi-asserted-by":"crossref","unstructured":"Quiroga MP, Balakrishnan K, Kurtova AV. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009; 114(5):1029-1037.","DOI":"10.1182\/blood-2009-03-212837"},{"key":"63329","doi-asserted-by":"crossref","unstructured":"Coffey GP, Feng J, Betz A. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies. Clin Cancer Res. 2019; 25(4):1174-1184.","DOI":"10.1158\/1078-0432.CCR-18-1047"},{"key":"63330","doi-asserted-by":"crossref","unstructured":"Hamlin PA, Flinn I, wagner-Johnston N. Clinical and correlative results of a phase 1 study of cerdulatinib (PRT062070) a dual SYK\/JAK inhibitor in patients with relapsed\/ refractory B cell malignancies. Blood. 2015; 126(23):3929.","DOI":"10.1182\/blood.V126.23.3929.3929"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282401\/76499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282401\/77183","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11408\/76499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:33Z","timestamp":1794045933000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282401","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}